Australia’s opportunity to turn biotech into global growth
How Australian biotech can use funding, clinical research and global markets to drive growth.
Beyond the numbers: Explore the trends and ideas shaping Australian business. Listen now.
08 Aug 2024 2 min read
The first round of data to be released this coming September (2024) will relate to the 2021-22 year. This initiative stems from the R&D reforms brought into effect from 1 July 2021.
The publication will detail the R&D entity's name, ABN, and the amount of R&D expenditure claimed (less any feedstock adjustments). A transparency report will accompany this data, offering insights into the figures released.
Reach out to Grant Thornton's Innovation Incentives specialists for expert advice and support.
Tax Agents Disclosures
The Tax Practitioners Board maintains a register of tax agents and BAS agents. You can access and search this register here.
Your engagement letter with Grant Thornton and the Standard Terms and Conditions set out our procedures for dealing with problems or complaints. The Tax Practitioners Board also has a complaints process in relation to tax agent services as outlined on their website which can be accessed here.
Section 45 of the Tax Agent Services (Code of Professional Conduct) requires Grant Thornton to notify you if it becomes aware of any matter which could significantly influence your decision to engage us or to continue to engage us in relation to the provision of tax agent services. Grant Thornton is not aware of any such matters.
How Australian biotech can use funding, clinical research and global markets to drive growth.
R&D Tax Incentive reforms, RDTI reforms, R&D tax offset, innovation incentives, refundable R&D offset, non-refundable R&D offset, supporting R&D activities, Treasury consultation, research and development tax incentive, Federal Budget 2026-27, R&D tax changes, Australia R&D incentives, Innovation Incentives, R&D claims
In this edition of our Australian International Tax Update, we summarise recent significant Australian tax developments, examine their practical impact, and outline actions that multinational groups, foreign investors, private equity funds and international advisers should consider.